相关实验视频

Updated: Jan 17, 2026

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

德克萨米他抑制了COVID-19中的内皮质病和内皮质诱导的凝血病

Aurélien Philippe^1,2, Romy Younan³, Nicolas Gendron^1,2

¹Université Paris-Cité, Institut national de la santé et de la recherche médicale (INSERM), Paris Cardiovascular Research Center (PARCC), France (A.P., N.G., X.L., J.R., L.K., O.S., C.M.B., J.-L.D., D.M.S.).

Arteriosclerosis, thrombosis, and vascular biology

|September 25, 2025

概括

德克萨米他治疗通过保护内皮,显著减少COVID-19引起的凝血病. 这一发现支持其用于管理严重的COVID-19并发症和降低血栓形成风险.

科学领域:

心血管医学心血管医学
血液学血液学血液学
传染性疾病传染性疾病

背景情况:

COVID-19与内脏病和凝血病有关,增加死亡风险.
德克萨米他是严重的COVID-19的标准治疗方法,但其机制尚不清楚.
调查德克萨米他对COVID-19相关的血凝前体内皮质病的影响至关重要.

研究的目的:

为了研究德克萨米他对COVID-19相关的前凝固性内皮病的功能后果.
为了确定德克萨米他是否减轻了导致COVID-19患者凝血病的内皮功能障碍.

主要方法:

前性队列研究测量COVID-19患者的内皮和凝血病生物标志物ARDS,有或没有德克萨米他和未分离氨酸 (UFH).
使用培养的人体内皮细胞进行体外血栓生成试验,以评估内源性血栓潜力 (ETP).

主要成果:

在ARDS患者中,用德克萨米他和UFH治疗显著降低了·威勒布兰德因子,Ang-2,可溶性E-选择素和d-二次体水平.
在体外,当内皮细胞被益炎性细胞因子激发时,甲,但不是UFH,显著降低了ETP.
与非ARDS患者相比,ARDS患者表现出更高的ETP,与未接受治疗的患者相比,用德甲治疗的ARDS患者的ETP显著降低.

结论:

德克萨米他治疗显示出对COVID-19引起的凝血病的保护作用.
这些发现与德克萨米他治疗COVID-19患者的静脉血栓发生率降低一致.
德克萨米他可能是管理COVID-19相关凝血病的关键治疗剂.

关键词:

德克萨米他是一种内皮细胞是内皮细胞.死亡率死亡率呼吸困扰综合征是呼吸困扰综合征.血栓形成的原因是血栓形成.

更多相关视频

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19

Published on: May 25, 2022

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...